[Captopril in congestive heart failure (author's transl)].
Captopril (Lopirin, Squibb, von Heyden) is an inhibitor of the angiotensin-I converting enzyme. In congestive heart failure angiotensin mediated vasoconstriction and aldosterone secretion is reversed by captopril. Both effects of captopril induce reduction of cardiac preload and afterload. The clinical state of patients with congestive heart failure therefore improves since cardiac output increased and pulmonary pressures decrease. Captopril acts orally and the dosage used for the treatment of congestive heart failure ranges from 50 to 150 mg daily. After oral ingestion of a single dose the maximum haemodynamic effect is observed after 45-90 min. No tolerance induction or tachyphylaxis has been observed during maintenance therapy over a period of 18 months. There are some reversible adverse reactions like pruritus, skin rash and partial or complete taste loss which are dose related. Serious side effects include leucopenia, agranulocytosis, renal failure and membranous glomerulonephritis. Therefore regular urinary and blood analysis is necessary during captopril therapy.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000380:Agranulocytosis / Q000139:chemically induced; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D004791:Enzyme Inhibitors; D005921:Glomerulonephritis / Q000139:chemically induced; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010447:Peptide Hydrolases / Q000378:metabolism; D011392:Proline / Q000031:analogs & derivatives*; D011537:Pruritus / Q000139:chemically induced; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D013651:Taste Disorders / Q000139:chemically induced
D004791:Enzyme Inhibitors; D011392:Proline; D002216:Captopril; D010447:Peptide Hydrolases; C027173:kininase III
Captopril bei Herzinsuffizienz.